333
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

, , , ORCID Icon, &
Pages 27-35 | Published online: 06 Mar 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Alex L Dubrava, Pan Su Pyae Kyaw, Joseph Newman, Jarrad Pringle, Justin Westhuyzen, Gina La Hera Fuentes, Thomas P Shakespeare, Renukadas Sakalkale & Noel J Aherne. (2023) Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?. Breast Cancer: Targets and Therapy 15, pages 359-371.
Read now
Rujing Chen, Shuting Ni, Wangyan Chen, Mei Liu, Jianfang Feng & Kaili Hu. (2021) Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles. International Journal of Nanomedicine 16, pages 5265-5279.
Read now

Articles from other publishers (6)

Lucia M. Balsa, María R. Rodriguez, Verónica Ferraresi-Curotto, Beatriz S. Parajón-Costa, Ana C. Gonzalez-Baró & Ignacio E. León. (2023) Finding New Molecular Targets of Two Copper(II)-Hydrazone Complexes on Triple-Negative Breast Cancer Cells Using Mass-Spectrometry-Based Quantitative Proteomics. International Journal of Molecular Sciences 24:8, pages 7531.
Crossref
Sinja Grosche, Natalia V. Bogdanova, Dhanya Ramachandran, Marcus Lüdeking, Katharina Stemwedel, Hans Christiansen, Christoph Henkenberens & Roland Merten. (2022) Effectiveness of hypofractionated and normofractionated radiotherapy in a triple‐negative breast cancer model. Frontiers in Oncology 12.
Crossref
Karen Cravero, Morgan V. Pantone, Dong Ho Shin, Riley Bergman, Rory Cochran, David Chu, Daniel J. Zabransky, Swathi Karthikeyan, Ian G. Waters, Natasha Hunter, D. Marc Rosen, Kelly Kyker-Snowman, W. Brian Dalton, Berry Button, Dan Shinn, Hong Yuen Wong, Joshua Donaldson, Paula J. Hurley, Sarah Croessmann & Ben Ho Park. (2022) NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model . Oncotarget 13:1, pages 373-386.
Crossref
Lucie G. Hallenstein, Carol Sorensen, Lorraine Hodgson, Shelly Wen, Justin Westhuyzen, Carmen Hansen, Andrew T. J. Last, Julan V. Amalaseelan, Shehnarz Salindera, William Ross, Allan D. Spigelman, Thomas P. Shakespeare & Noel J. Aherne. (2021) Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia. Hereditary Cancer in Clinical Practice 19:1.
Crossref
Aron Gortman, Noel Aherne, Justin Westhuyzen, Julan Amalaseelan, Patrick Dwyer, Matthew Hoffmann, Andrew Last & Thomas Shakespeare. (2021) Metaplastic carcinoma of the breast: Clinicopathological features and treatment outcomes with long‑term follow up. Molecular and Clinical Oncology 15:3.
Crossref
Sijia Wu, Jiachen Wang, Xinchao Zhu, Jacqueline Chyr, Xiaobo Zhou, Xiaoming Wu & Liyu Huang. (2021) The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer. Frontiers in Genetics 11.
Crossref